StreetInsider.com News Articles

MediciNova receives patent allowance for glioblastoma combination therapy

Mon, 08 Jun 2026 08:00:09 -0400

MediciNova Inc. (NASDAQ: MNOV) received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the use of ibudilast (MN-166) in combination with anti-PD-1 antibodies for treating glioblastoma, the company announced.

The patent, expected to expire no earlier than September 2042, covers multiple treatment parameters including dosing regimen, route of administration, and duration of therapy. The allowed claims encompass combinations with multiple anti-PD-1 antibodies across various treatment conditions.

"This Notice of Allowance further strengthens our intellectual property estate for MN-166 in glioblastoma and supports continued evaluation of ibudilast-based combination strategies in this aggressive malignancy," said Dr.

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Mon, 08 Jun 2026 08:00:00 -0400

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application that covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for the treatment of glioblastoma. This patent allowance is expected to further strengthen the intellectual property position supporting the Company’s combination therapy development strategy.

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Mon, 08 Jun 2026 08:00:00 -0400

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Tue, 26 May 2026 19:00:00 -0400

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).

The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Tue, 26 May 2026 19:00:00 -0400

The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001

Form 10-Q MEDICINOVA INC For: Mar 31

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495212.html

Form 10-Q MEDICINOVA INC For: Mar 31

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495212.html

Form ARS MEDICINOVA INC For: Dec 31

Wed, 29 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260429/26395794.html

Form ARS MEDICINOVA INC For: Dec 31

Wed, 29 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260429/26395794.html

Form DEFA14A MEDICINOVA INC

Wed, 29 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26395711.html

Form DEFA14A MEDICINOVA INC

Wed, 29 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26395711.html

Form DEF 14A MEDICINOVA INC For: Jun 23

Wed, 29 Apr 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260429/26395460.html

Form DEF 14A MEDICINOVA INC For: Jun 23

Wed, 29 Apr 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260429/26395460.html

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation